ZEAL
ZEALAND PHARMA A/S-ADR
$17.59
Earnings Summary
Revenue | $10.8Mn |
Net Profits | $-93.68Mn |
Net Profit Margins | -867.2% |
Highlights
ZEALAND PHARMA A/S-ADR’s revenue jumped 35.94% since last year same period to $10.8Mn in the Q2 2017. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -86.08% fall in its revenue since last 3-months.
ZEALAND PHARMA A/S-ADR’s net profit jumped 4.35% since last year same period to $-93.68Mn in the Q2 2017. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -255.81% fall in its net profits since last 3-months.
ZEALAND PHARMA A/S-ADR’s net profit margin jumped 29.64% since last year same period to -867.2% in the Q2 2017. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -2456.74% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the ZEALAND PHARMA A/S-ADR post its latest quarter earnings
EPS Estimate Current Quarter | -6.61 |
EPS Estimate Current Year | -6.61 |
Highlights
ZEALAND PHARMA A/S-ADR’s earning per share (EPS) estimates for the current quarter stand at -6.61 - a -3.44% fall from last quarter’s estimates.
ZEALAND PHARMA A/S-ADR’s earning per share (EPS) estimates for the current year stand at -6.61.
Key Ratios
Key ratios of the ZEALAND PHARMA A/S-ADR post its Q1 2022 earnings
Earning Per Share (EPS) | -5.16 |
Return on Assets (ROA) | -0.34 |
Return on Equity (ROE) | -0.94 |
Highlights
ZEALAND PHARMA A/S-ADR’s earning per share (EPS) jumped 10.73% since last year same period to -5.16 in the Q1 2022. This indicates that the ZEALAND PHARMA A/S-ADR has generated 10.73% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ZEALAND PHARMA A/S-ADR’s return on assets (ROA) stands at -0.34.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ZEALAND PHARMA A/S-ADR’s return on equity (ROE) stands at -0.94.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2017-12-31 | -0.5 | -0.61 | -22.38% |
2017-09-30 | -0.37 | -0.23 | 36.87% |
Company Information
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Organisation | ZEALAND PHARMA A/S-ADR |
CEO | Emmanuel Dulac |
